Pharmaceuticals, Biotechnology and Life Sciences
Roche Diabetes Care France, a healthcare company specializing in diabetes, will distribute Mallya to pharmacies in France to pharmacists and will integrate it into its Roche Diabetes digital ecosystem.
Pharmaceutical company Adalvo today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for Livogiva, indicated for use in postmenopausal women with osteoporosis who are at high risk of having bone fractures.
Centogene has partnered exclusively with Lufthansa and with Fraport, the operator of Frankfurt Airport, to offer COVID-19 testing to passengers flying to and from Frankfurt Airport (FRA).
Vertex Pharmaceutical said on Friday in a press release that, if Kaftrio combined with Kalydeco is granted Marketing Authorization, people ages 12 and older in Europe who have one F508del mutation and one minimal function mutation will for the first time be able to benefit from a medicine that treats the underlying cause of the disease.
Reblozyl regulates late-stage red blood cell (RBC) maturation to potentially reduce or eliminate the need for regular RBC transfusions Reblozyl…
Scientists from UK-headquartered AI precision medicine company, PrecisionLife, have found 68 genes associated with risk of developing severe COVID-19 by using its proprietary AI-enabled precision medicine platform to analyze the genomes of 929 patients from the UK Biobank who had a severe response to SARS-CoV-2.
Clinerion’s Patient Network Explorer adds new, actionable functionality to support clinical trial sponsors during site selection as a result of Clinerion’s collaboration with LongTaal, a clinical trial informatics company.
Sanofi on Tuesday detailed plans investing in France to increase its vaccines research and production capacities, and contribute in responding to future pandemic risks, aligned with its corporate strategy presented last December, Sanofi will invest €610 million to create a new production site and research center in France with both dedicated to vaccines.
Tilt Biotherapeutics has secured an additional EUR 6.2m, including EUR 4.5m equity, to advance its proprietary, best-in-class cytokine armed oncolytic adenovirus, TILT-123, into Phase 1 clinical trials
The Federal Republic of Germany will invest 300 million Euros in the biopharmaceutical company CureVac AG, a pioneer in the preclinical and clinical development of mRNA-based drugs.